Search Results Sort by RelevanceMost Recent State of the Art and Science Nov 2003 The Genomic Era: What MUST Public Health Do? Shane K. Green, PhD Virtual Mentor. 2003;5(11):380-382. doi: 10.1001/virtualmentor.2003.5.11.gene1-0311. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Policy Forum Sep 2009 Emerging Dilemmas in Newborn Screening Don B. Bailey, Jr, PhD, Debra Skinner, PhD, Myra I. Roche, MS, CGC, and Cynthia Powell, MD, MS Virtual Mentor. 2009;11(9):709-713. doi: 10.1001/virtualmentor.2009.11.9.pfor2-0909. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Medicine and Society Dec 2019 An Exclusive Interview With CRISPR Sean C. McConnell, PhD Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy. AMA J Ethics. 2019;21(12):E1079-1088. doi: 10.1001/amajethics.2019.1079.